Financial Summary (All financials)
In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
Revenues | 3,217.2 | 3,236.7 | 3,010.6 | 2,973.9 | 2,824.7 | 2,736.1 | 2,646.2 | 3,142.9 |
Revenue growth | -0.6% | 7.5% | 1.2% | 5.3% | 3.2% | 3.4% | -15.8% | 7.7% |
Cost of goods sold | 625.1 | 498.5 | 464.0 | 433.8 | 439.6 | 404.9 | 474.0 | 620.2 |
Gross profit | 2,592.1 | 2,738.2 | 2,546.5 | 2,540.1 | 2,385.0 | 2,331.2 | 2,172.1 | 2,522.6 |
Gross margin | 80.6% | 84.6% | 84.6% | 85.4% | 84.4% | 85.2% | 82.1% | 80.3% |
Sales and marketing | 1,194.7 | 1,224.4 | 1,133.0 | 1,074.2 | 1,006.1 | 976.3 | 1,005.8 | 1,280.3 |
Research and development | 581.6 | 538.1 | 518.9 | 440.0 | 415.8 | 395.4 | 481.0 | 553.8 |
General and administrative | 409.6 | 352.1 | 320.4 | 315.3 | 302.6 | 316.8 | 286.4 | 319.9 |
EBITA | 694.3 | 665.7 | 625.6 | 740.9 | 653.9 | 698.1 | 526.2 | 515.1 |
EBITA margin | 21.6% | 20.6% | 20.8% | 24.9% | 23.1% | 25.5% | 19.9% | 16.4% |
Amortization of intangibles | 157.7 | 35.6 | 67.2 | 62.9 | 82.9 | 70.5 | 224.8 | 192.3 |
EBIT | 536.6 | 630.1 | 558.4 | 678.0 | 571.0 | 627.6 | 301.5 | 322.7 |
EBIT margin | 16.7% | 19.5% | 18.5% | 22.8% | 20.2% | 22.9% | 11.4% | 10.3% |
Pre-tax income | 167.1 | 554.9 | 509.5 | 629.5 | 550.3 | 527.8 | 164.6 | 275.7 |
Income taxes | -140.4 | 50.4 | -172.3 | 53.8 | 528.4 | 57.9 | -50.5 | 24.0 |
Tax rate | | 9.1% | | 8.5% | 96.0% | 11.0% | | 8.7% |
Earnings from continuing ops | 307.5 | 504.4 | 681.8 | 575.7 | 22.0 | 469.9 | 215.1 | 251.7 |
Earnings from discontinued ops | | | | | 0.0 | | | |
Net income | 307.5 | 504.4 | 681.8 | 575.7 | -20.7 | 536.1 | 319.4 | 251.7 |
Net margin | 9.6% | 15.6% | 22.6% | 19.4% | -0.7% | 19.6% | 12.1% | 8.0% |
|
Diluted EPS | $2.44 | $4.00 | $5.03 | $3.94 | $0.14 | $2.99 | $1.34 | $1.47 |
Shares outstanding (diluted) | 126.3 | 126.2 | 135.5 | 145.9 | 155.5 | 157.1 | 160.4 | 171.3 |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|